Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35448| Title: | Treatment of severe hypertension during pregnancy: we still do not know what the best option is. | Authors: | Costa F.D.S.;Mol B.W.J. ;Rolnik D.L. ;Reddy M. ;Wang R.;Wertaschnigg D. | Monash Health Department(s): | Obstetrics and Gynaecology (Monash Women's) | Institution: | (Wertaschnigg, Wang, Reddy, Costa, Mol, Rolnik) Department of Obstetrics and Gynecology, Monash University, Clayton, Australia (Wertaschnigg) Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria (Reddy, Mol, Rolnik) Monash Women's, Monash Health, Clayton, Australia (Costa) Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil | Issue Date: | 18-Feb-2020 | Copyright year: | 2020 | Publisher: | Taylor and Francis Ltd | Place of publication: | United States | Publication information: | Hypertension in Pregnancy. 39 (1) (pp 25-32), 2020. Date of Publication: 02 Jan 2020. | Journal: | Hypertension in Pregnancy | Abstract: | Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both-mother and fetus-is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians' preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.Copyright © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/10641955.2019.1708383 | PubMed URL: | 31880480 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31880480] | ISSN: | 1064-1955 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/35448 | Type: | Review | Subjects: | therapy effect *antihypertensive agent/dt [Drug Therapy] hydralazine labetalol nifedipine chronic disease *antihypertensive therapy blood pressure comorbidity disease severity drug efficacy drug safety female fetus outcome human *maternal hypertension/dt [Drug Therapy] maternal mortality outcome assessment perinatal morbidity preeclampsia pregnancy pregnancy outcome randomized controlled trial (topic) review therapy effect antihypertensive agent hydralazine labetalol nifedipine chronic disease antihypertensive therapy blood pressure drug efficacy drug safety fetus outcome maternal hypertension maternal perinatal preeclampsia pregnancy pregnancy outcome maternal mortality outcome assessment perinatal morbidity preeclampsia pregnancy pregnancy outcome randomized controlled trial (topic) Review chronic disease blood pressure *antihypertensive therapy therapy effect comorbidity disease severity drug efficacy drug safety female fetus outcome human *maternal hypertension / *drug therapy |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.